X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As PNT001 is a humanized version of this antibody, this study provides further evidence for the ability of PNT001 to treat the cognitive impairments seen in tauopathies like Alzheimer’s disease and other neurodegenerative disorders.
Lead Product(s): PNT001
Therapeutic Area: Neurology Product Name: PNT001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease.
Lead Product(s): PNT001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PNT001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Advanced Technology International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 17, 2021
Details:
PNT001 is a monoclonal antibody targeting an epitope on a highly neurotoxic conformation of the tau protein called cis-pT231 tau. According to the data, PNT001 was demonstrated to be well-tolerated in healthy volunteers.
Lead Product(s): PNT001
Therapeutic Area: Neurology Product Name: PNT001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
